Q-omics provides the consensus-scored SDHCP4 profile across patient tissues and cancer cell-line models. SDHCP4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, SDHCP4 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SDHCP4 RNA expression shows 7,131 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, KICH, and GBM as cancer lineages where SDHCP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHCP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHCP4 survival associations across molecular data types. SDHCP4 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHCP4 RNA expression–survival associations across cancer types. High SDHCP4 expression shows unfavorable associations in DLBC, MESO, KICH and SARC, but favorable associations in LGG and PAAD. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for SDHCP4 RNA expression.
This table summarizes SDHCP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SDHCP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHCP4 shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in BRCA, COAD and PAAD. The KICH box plot shows higher SDHCP4 RNA expression in normal versus tumor tissue (log2 FC = −0.133, t-test p < 0.001).
This table shows molecular features associated with SDHCP4 in patient tissues and cancer cell lines. In patient samples, SDHCP4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
